Skip to navigation bar Skip to breadcrumbs Skip to page content Skip to comments area
clear place holder Browse All Topics Envelope icon E-mail Updates Teal square Text size:  a A A
You are here: HomePublic Comments and NominationsOpportunity for Public CommentDraft Recommendation Statement : Draft Recommendation Statement

Draft Recommendation Statement

Iron Deficiency Anemia in Pregnant Women: Screening and Supplementation

This opportunity for public comment expired on April 27, 2015 at 8:00 PM EST

Note: This is a Draft Recommendation Statement. This draft is distributed solely for the purpose of receiving public input. It has not been disseminated otherwise by the USPSTF. The final Recommendation Statement will be developed after careful consideration of the feedback received and will include both the Research Plan and Evidence Review as a basis.

Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Send Us Your Comments

In an effort to maintain a high level of transparency in our methods, we open our draft Recommendation Statements to a public comment period before we publish the final version.

Comment period is not open at this time.

Draft: Recommendation Summary

PopulationRecommendationGrade
(What's This?)
Pregnant women

The U.S. Preventive Services Task Force concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for iron deficiency anemia in pregnant women to prevent adverse maternal health and birth outcomes.

The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.
Pregnant women

The U.S. Preventive Services Task Force concludes that the current evidence is insufficient to assess the balance of benefits and harms of routine iron supplementation for pregnant women to prevent adverse maternal health and birth outcomes.

The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.

Go to the Clinical Considerations section for suggestions for practice regarding the I statements.

Draft: Preface

The USPSTF makes recommendations about the effectiveness of specific preventive care services for patients without related signs or symptoms.

It bases its recommendations on the evidence of both the benefits and harms of the service, and an assessment of the balance. The USPSTF does not consider the costs of providing a service in this assessment.

The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decisionmaking to the specific patient or situation. Similarly, the USPSTF notes that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms.

Draft: Rationale

Importance

Few data are available to estimate the current prevalence of iron deficiency anemia in pregnant women in the United States. Based on older data from 1999 to 2006, an estimated 18.6% of pregnant women have iron deficiency; of those, an estimated 16.2% have anemia.1 Rates may be higher in low-income and minority populations.1, 2

Detection and Recognition of Risk Status

The USPSTF found inadequate evidence that specifically addressed the accuracy of screening tests in asymptomatic pregnant women. The USPSTF found inadequate evidence to evaluate risk prediction tools to identify pregnant women who are at increased risk for iron deficiency.

Benefits of Early Detection and Treatment

Screening

The USPSTF found inadequate evidence on screening for iron deficiency anemia in asymptomatic pregnant women. No studies evaluated the direct effects of routine screening in asymptomatic pregnant women on maternal health or birth outcomes. The USPSTF also found inadequate evidence on the treatment of iron deficiency anemia in pregnant women, as none of the recent studies on treatment were generalizable to the general U.S. population. This represents a critical gap in the evidence.

Preventive Medication

Overall, the USPSTF found inadequate evidence on the benefit of routine iron supplementation during pregnancy on maternal health or birth outcomes, such as maternal iron deficiency anemia, Cesarean delivery, preterm delivery, infant mortality, or low birthweight. Several studies reported inconsistent findings on these health outcomes. The USPSTF found adequate evidence that routine iron supplementation during pregnancy improves intermediate maternal hematological indexes, such as serum ferritin and hemoglobin levels. The USPSTF found adequate evidence that routine iron supplementation during pregnancy has no effects on length of gestation and infant Apgar scores at 1 and 5 minutes.

Change in Iron Status

The USPSTF found no studies that directly assessed the association between change in iron status as a result of treatment or supplementation and improvement in maternal or infant health outcomes. This represents a critical gap in the evidence.

Harms of Early Detection and Treatment

Screening

The USPSTF found inadequate evidence on the harms of routine screening for iron deficiency anemia in asymptomatic pregnant women. The USPSTF found no studies that evaluated the harms of routine screening on maternal health or birth outcomes. The USPSTF found inadequate evidence on the harms of treatment of iron deficiency anemia in pregnant women. The USPSTF found no recent studies that were generalizable to the current general U.S. population.

Preventive Medication

The USPSTF found adequate evidence that the magnitude of the harms of routine iron supplementation in pregnant women is small to none. The USPSTF found several studies that assessed the harms of iron supplementation in pregnant women. Most reported no statistically significant increase in harms. Of the harms reported, most were self-limited and transient effects of treatment, such as nausea, constipation, and diarrhea.

USPSTF Assessment

The USPSTF concludes that the evidence on routine screening for iron deficiency anemia in asymptomatic pregnant women to prevent adverse maternal health and birth outcomes is insufficient, and the balance of benefits and harms cannot be determined.

The USPSTF concludes that the evidence on routine iron supplementation in pregnant women to prevent adverse maternal health and birth outcomes is insufficient, and the balance of benefits and harms cannot be determined.

Draft: Clinical Considerations

Patient Population Under Consideration

This recommendation addresses screening and supplementation in pregnant adolescents and women living in the United States who do not have symptoms of iron deficiency or anemia. It does not address pregnant women who are malnourished, have symptoms of iron deficiency or iron deficiency anemia, or have special hematological conditions or nutritional needs that may increase their need for iron. Screening for iron deficiency anemia in young children is addressed in a separate recommendation statement (available at www.uspreventiveservicestaskforce.org).

Suggestions for Practice Regarding the I Statements

Potential Preventable Burden

Based on older data, estimates of the prevalence of iron deficiency anemia in pregnant women in the United States range from 2% to 27%, with higher rates in later trimesters and in minority populations.2 Based on calculations of total body iron from 1999–2006 National Health and Nutrition Examination Survey (NHANES) data, the estimated prevalence of iron deficiency in pregnant women is 18.6%; 16.2% of these women also have anemia.1 However, given the physiological hemodilution that normally occurs during the later stages of pregnancy, determining exact prevalence rates of anemia in pregnant women may be difficult. Numerous observational studies have explored the association between adverse maternal and infant health outcomes (such as postpartum hemorrhage, preterm birth, low birthweight, and perinatal death) and iron deficiency or iron deficiency anemia in pregnancy, with inconclusive findings.2 The aims of iron supplementation or screening for and treatment of iron deficiency anemia in pregnant women are to improve maternal and infant health outcomes.

Potential Harms

The harms of screening for iron deficiency anemia have not been well studied. Potential harms of screening include false-positive results, anxiety, and cost. Reported adverse events of iron supplementation or treatment with iron include limited gastrointestinal symptoms, darkening color of urine or stool, staining of teeth and gums, and drug interactions with other medications.

Current Practice

Rates of screening for iron deficiency anemia and iron supplementation in pregnant women by clinicians are not well documented. However, based on anecdotal evidence, it is likely quite common. In addition, there may be other reasons to screen for anemia in pregnant women, such as to prepare for Cesarean delivery or anticipated blood loss during a complicated delivery. Based on older data from 1988, 97% of pregnant women who received prenatal care reported being advised to take a multivitamin–mineral supplement.3 Based on NHANES data from 1999 to 2006, 77% of pregnant women reported using a supplement within the previous 30 days, most frequently a multivitamin containing 48 mg of iron.4

Assessment of Risk

The USPSTF found limited evidence on the use of risk prediction tools to identify pregnant women who are at increased risk for iron deficiency anemia. However, several factors have been identified that may increase a pregnant woman's risk for iron deficiency anemia, including a diet lacking in iron-rich foods (e.g., vegetarian diet with inadequate sources of iron), having gastrointestinal issues or taking medications that can decrease iron absorption (e.g., antacids), and a short interval between pregnancies. Non-Hispanic black and Mexican American women have higher prevalence rates of iron deficiency than white women and women with parity of two or more. Evidence on additional risk factors, such as lower educational level and family income, has been less consistent.

Treatment

Treatment of iron deficiency anemia in pregnant women is similar to that in nonpregnant women and includes additional iron intake through oral iron pills, prenatal vitamins, and diet. The usual dose is 60 to 120 mg of elemental iron per day.2, 5

Other Approaches to Prevention

According to the Institute of Medicine, the Recommended Dietary Allowance for iron in pregnant women is 27 mg per day. Natural food sources of iron include certain fruits, vegetables, meat, and poultry. The Institute of Medicine also notes that nonheme iron, which is found in vegetarian diets, may be less well absorbed than heme iron, which is found in diets containing meat; therefore, the iron requirement may be almost twice as much in women who eat a purely vegetarian diet.6 Fortified breads and grain products (such as cereal) are also good sources of iron.7, 8 Federally-regulated iron fortification of food products in the United States began in 1941, and the iron content in enriched grain products has increased over the years.7 It is estimated that more than 50% of the iron in the U.S. food supply comes from iron-fortified cereal grain products.7, 8

Useful Resources

The USPSTF has published separate recommendation statements on screening for iron deficiency anemia in young children and folic acid supplementation during pregnancy (available at www.uspreventiveservicestaskforce.org).

Draft: Other Considerations

Research Needs and Gaps

Studies that directly evaluate the effects of screening for and early treatment of iron deficiency anemia on maternal and infant health outcomes are needed. Although adequate evidence shows that iron supplementation improves maternal hematological indexes, the clinical significance of this improvement needs to be clarified. Well-designed and adequately-powered studies that evaluate the effects of iron supplementation, or change in maternal iron status as a result of intervention, on maternal and infant health outcomes (e.g., postpartum hemorrhage, maternal morbidity, preterm delivery, low birthweight, and perinatal death) are needed, particularly in settings similar to the United States with respect to nutrition, hemoparasite burden, and socioeconomic status.

Draft: Discussion

Burden of Disease

Iron is necessary for the production of hemoglobin, an essential protein found in red blood cells. During pregnancy, iron is also needed for the development of the fetus and placenta and to expand maternal red blood cell mass. Iron deficiency occurs when body stores of iron become depleted. Iron deficiency anemia results when iron stores become so low that hemoglobin synthesis is impaired, causing anemia. Iron deficiency can occur when there is an increased need for iron (e.g., during pregnancy) or when there is decreased iron intake and absorption (e.g., lack of iron sources in the diet).

Current data on the prevalence of iron deficiency anemia in pregnant women in the United States are lacking. Based on older data from a cohort of mostly racial/ethnic minority women, the estimated prevalence of iron deficiency anemia in pregnant women ranges from as low as 1.8% during the first trimester to as high as 27.4% during the third trimester.9 Based on calculations of total body iron from 1999–2006 NHANES data, the estimated prevalence of iron deficiency in pregnant women is 18.6%, ranging from 6.9% in the first trimester to 29.5% in the third trimester.1

The major concern about iron deficiency anemia and iron deficiency in pregnant women is whether it has adverse effects on maternal health or infant outcomes. Older observational studies suggest an association between adverse outcomes in infants and anemia in the early stages of pregnancy but not during the third trimester.2 Although iron supplementation and treatment during pregnancy have been observed to improve hemoglobin levels and iron status, the clinical significance of this finding is not clear, and the evidence on maternal and infant health outcomes is limited.10 Furthermore, studies evaluating these outcomes are often conducted in countries whose nutritional status and hemoparasite burden vary significantly from that of the United States.

Scope of Review

The USPSTF commissioned an updated systematic evidence review to update its 2006 recommendation on screening for iron deficiency anemia. The USPSTF focused on reviewing the evidence on the association between change in iron status as a result of intervention (supplementation or treatment) in pregnant women, including adolescents, and improvement in maternal and infant health outcomes. The current review also focused on the treatment of iron deficiency anemia with oral iron formulations (i.e., not intravenous iron). The USPSTF considered studies conducted in settings similar to the United States in rates of malnutrition, hemoparasite burden, and general socioeconomic status.

Accuracy of Screening Tests

Serum hemoglobin or hematocrit is the primary screening test for anemia. However, given the hemodilution and physiological anemia that normally occurs during pregnancy, using hemoglobin or hematocrit measurement alone to determine iron deficiency status can be imprecise, and its sensitivity and specificity for detecting iron deficiency anemia in pregnant women is unknown. Serum ferritin, which is often used to measure iron status, has limited use during pregnancy, as its concentration often decreases in late pregnancy despite adequate iron stores in the bone marrow. Also, serum ferritin is an acute phase reactant, meaning its levels increase during periods of inflammation.11

Effectiveness of Early Detection and Treatment

Screening and Treatment

No good- or fair-quality studies directly evaluated the effectiveness of screening for iron deficiency anemia in asymptomatic pregnant women and adolescents on maternal or infant health outcomes. In addition, no new studies that would be applicable to the current U.S. population evaluated oral iron treatment of iron deficiency anemia in asymptomatic pregnant women.

Supplementation

Twelve good- or fair-quality randomized, controlled trials evaluated the effects of iron supplementation on various maternal hematological indexes, including hemoglobin level, serum ferritin level, anemia, iron deficiency, and iron deficiency anemia. Eight studies were conducted in the United States or Europe, three in Iran, and one in Hong Kong; sample sizes ranged from 45 to 1,164 participants. Supplement doses ranged from 20 to 120 mg per day and outcomes were measured at various timepoints, from the second trimester to postpartum.2 Overall, the evidence was most consistent on improvement in hemoglobin and ferritin levels. Of the eight studies12-19 reporting maternal hemoglobin levels at term or delivery, six12, 13, 15, 17–19 reported a significantly higher mean hemoglobin level in the supplemented versus control groups (122 to 139 g/L vs. 115 to 128 g/L, respectively). Of the seven studies13–19 reporting serum ferritin levels at term or delivery, five13, 15, 17–19 reported a significantly higher ferritin level in the supplemented versus control groups (12.0 to 30.0 µg/L vs. 6.2 to 24.9 µg/L, respectively). Although adequate evidence shows that supplementation increases hemoglobin and ferritin levels, the evidence is unclear whether this increase leads to an improvement in maternal and fetal health outcomes. In most of these studies, the supplemented groups had higher mean hemoglobin levels than the nonsupplemented groups; however, both groups reported values within normal limits. Evidence on the effects of supplementation on maternal iron deficiency anemia and anemia was inconsistent.

Five trials12, 13, 15, 17, 20 evaluated the effects of iron supplementation during pregnancy on maternal health outcomes (e.g., Cesarean delivery and quality of life) and 11 trials12–18, 20–23 evaluated various infant birth outcomes (e.g., preterm delivery, low birthweight, small for gestational age, and infant mortality). Studies were conducted in the United States, Australia, Hong Kong, Ireland, Iran, and Norway; sample sizes ranged from 45 to 1,164 participants. Studies used varying doses of iron, ranging from 20 to 200 mg per day. Studies on Cesarean delivery and maternal quality of life were sparse or reported inconsistent results. Studies on individual infant birth outcomes were sparse, frequently underpowered, or overall reported inconsistent findings. Only four studies reported on infant mortality12, 13, 17, 20, and none reported a significant difference with prenatal iron supplementation. However, given the relatively low frequency of this outcome, studies were likely underpowered to detect a change, and none reported power calculations for this outcome. Evidence on the effects of supplementation on birthweight were mixed. Of the eight studies14–18, 21–23 reporting this outcome, three15, 21, 22 found that women receiving iron supplementation during pregnancy gave birth to infants with a significantly higher mean birthweight (95 to 205 g more) than women not receiving iron supplementation; however, both groups reported values within normal limits.2 Of the six studies reporting on low birthweight12, 13, 16, 17, 21, 22, only one21 found a significantly lower rate of low-birthweight infants; however, these studies may have been underpowered to detect a change.

Similarly, of four studies15, 20, 21, 22 reporting on small for gestational age infants, one study22 reported no significant difference in rates between supplemented and unsupplemented groups, two studies15, 21 reported fewer small for gestational age infants in supplemented groups, and one study20 reported more small for gestational age infants in the supplemented group. Overall, the USPSTF found inadequate evidence on the effectiveness of supplementation during pregnancy.

No good- or fair-quality studies that would be applicable to the current U.S. population2 evaluated the association between change in iron status as a result of intervention (supplementation or treatment) and improvement in maternal or infant health outcomes.

Potential Harms of Screening and Treatment

Screening and Treatment

No good- or fair-quality studies reported on the harms of screening or early treatment.2 Potential harms of iron treatment include gastrointestinal symptoms.

Supplementation

Ten trials12–17, 20–23 reported on harms of routine iron supplementation during pregnancy. Studies were conducted in the United States, Ireland, Hong Kong, Norway, Iran, and Australia, and sample sizes ranged from 45 to 1,164 participants. Supplementation doses ranged from 20 to 200 mg per day. Most reported harms, including nausea, constipation, and diarrhea, were transient and not serious. Generally, there was no significant difference between supplemented and control groups. Reported rates of nausea ranged from 29% to 63% in supplemented groups and 28% to 65% in control groups. Reported rates of vomiting ranged from 12% to 41% in supplemented groups and 15% to 41% in control groups. Reported rates of constipation (or bowel movement ≤3 times per week) ranged from 4% to 29% in supplemented groups and 1.6% to 28% in control groups. Evidence on supplementation and maternal hypertension was inconsistent, ranging from 1.4% to 7.5% in supplemented groups and 0% to 9% in control groups.2 Overall, the USPSTF found adequate evidence that the harms of supplementation are small to none.

Estimate of Magnitude of Net Benefit

Screening and Early Detection

Overall, the USPSTF found insufficient evidence on screening for iron deficiency anemia in asymptomatic pregnant women and adolescents. The USPSTF found no good- or fair-quality studies that evaluated the benefits or harms of screening in this population. The USPSTF found a single older poor-quality study on the benefits and harms of treatment that was not considered to be applicable to the current U.S. pregnant population. Despite the absence of proven harms of screening, the USPSTF did not find sufficient evidence to determine that the benefits of screening outweigh the potential harms.

Supplementation

Overall, the USPSTF found insufficient evidence on the effects of iron supplementation during pregnancy. Although the USPSTF found adequate evidence on harms and deemed them to be small to none, it found inadequate evidence on benefits. Reported benefits of supplementation were limited to intermediate outcomes (maternal hematological indexes), and evidence on the benefits of supplementation on maternal and infant health outcomes was inadequate due to inconsistent results and underpowered studies. The USPSTF did not find sufficient evidence to determine that the benefits of supplementation outweigh the potential harms.

How Does Evidence Fit With Biological Understanding?

Based on older observational data, the association between negative iron status during pregnancy and adverse maternal and infant health outcomes is inconsistent. Some findings indicate that anemia occurring earlier in pregnancy may be associated with serious adverse infant outcomes, while anemia occurring during the third trimester may not. Evidence on the association between improvement in maternal iron status and improvement in maternal and infant health outcomes is lacking. While treatment and supplementation with oral iron can improve maternal hematological indexes (most often, hemoglobin and serum ferritin), subsequent improvement in maternal and infant outcomes has not been well demonstrated. This raises the question as to whether the timing of identification and correction of iron deficiency anemia plays an important role, and whether currently used measures of iron deficiency anemia (primarily hemoglobin, hematocrit, and ferritin) are effective in identifying women who may need additional iron during pregnancy, given the normal occurrence of physiological anemia and the limitations of interpreting ferritin levels.

Draft: Update of Previous USPSTF Recommendation

This recommendation is consistent with the 2006 recommendation statement on iron supplementation during pregnancy. Both the 2006 and the current recommendation statement found insufficient evidence to determine the balance of the benefits and harms of iron supplementation during pregnancy. While the 2006 statement also recommended screening for iron deficiency anemia in pregnant women, the current recommendation found insufficient evidence to recommend for or against screening. In its review of the evidence to update the 2006 recommendation, the USPSTF found no good- or fair-quality studies on the benefits or harms of screening that would be applicable to the current U.S. pregnant population. Since 2006, the USPSTF has updated its methodology to better identify evidence that would be most applicable to the current U.S. population. Therefore, the USPSTF determined that the currently available and applicable evidence on screening for and early treatment of iron deficiency anemia in pregnant women is insufficient.

Send Us Your Comments

In an effort to maintain a high level of transparency in our methods, we open our draft Recommendation Statements to a public comment period before we publish the final version.

Comment period is not open at this time.

Draft: Recommendations of Others

In 1998, the Centers for Disease Control and Prevention recommended screening for anemia and initiating low-dose iron supplementation at the first prenatal care visit for all pregnant women.5 The Institute of Medicine recommends screening for anemia in each trimester of pregnancy.24 The American Congress of Obstetricians and Gynecologists recommends screening all pregnant women for anemia and treating those with iron deficiency anemia with supplemental iron. It also states that it is unclear whether iron supplementation in well-nourished pregnant women without anemia affects perinatal outcomes.25 The American Academy of Family Physicians is currently updating its recommendation.26

References

1. Mei Z, Cogswell ME, Looker AC, Pfeiffer CM, Cusick SE, Lacher DA, et al. Assessment of iron status in US pregnant women from the National Health and Nutrition Examination Survey (NHANES), 1999-2006. Am J Clin Nutr. 2011;96(6):897-9.
2. McDonagh M, Cantor A, Bougatsos C, Dana T, Blazina I. Routine Iron Supplementation and Screening for Iron Deficiency Anemia in Pregnant Women: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation. Evidence Synthesis No. 123. AHRQ Publication No. 13-05187-EF-2. Rockville, MD: Agency for Healthcare Research and Quality; 2015.
3. Yu SM, Keppel KG, Singh GK, Kessel W. Preconceptional and prenatal multivitamin-mineral supplement use in the 1988 National Maternal and Infant Health Survey. Am J Public Health. 1996;86(2):240-2.
4. Branum AM, Bailey R, Singer BJ. Dietary supplement use and folate status during pregnancy in the United States. J Nutr. 2013;143(4):486-92.
5. Centers for Disease Control and Prevention. Recommendations to prevent and control iron deficiency in the United States. MMWR Recomm Rep. 1998;47(RR-3):1-29.
6. Otten JJ, Hellwig JP, Meyers LD, eds. Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. Washington, DC: National Academies Press; 2006.
7. Backstrand JR. The history and future of food fortification in the United States: a public health perspective. Nutr Rev. 2002;60(1):15-26.
8. Gerrior S, Bente L, Hiza H. Nutrient Content of the U.S. Food Supply, 1909−2000. Washington, DC: U.S. Department of Agriculture, Center for Nutrition Policy and Promotion; 2004.
9. Scholl TO. Iron status during pregnancy: setting the stage for mother and infant. Am J Clin Nutr. 2005;81(5):1218S-22.
10. Reveiz L, Gyte GML Cuervo LG, Casasbuenas A. Treatments for iron-deficiency anaemia in pregnancy. Cochrane Database Syst Rev. 2011;(10):CD003094.
11. World Health Organization. Serum Ferritin Concentrations for the Assessment of Iron Status and Iron Deficiency in Populations. Geneva: World Health Organization; 2011. Accessed at http://www.who.int/vmnis/indicators/ferritin/en/ on 12 March 2015.
12. Barton DP, Joy MT, Lappin TR, Afrasiabi M, Morel JG, O'Riordan J, et al. Maternal erythropoietin in singleton pregnancies: a randomized trial on the effect of oral hematinic supplementation. Am J Obstet Gynecol. 1994;170(3):896-901.
13. Meier PR, Nickerson HJ, Olson KA, Berg RL, Meyer JA. Prevention of iron deficiency anemia in adolescent and adult pregnancies. Clin Med Res. 2003;1(1):29-36.
14. Romslo I, Haram K, Sagen N, Augensen K. Iron requirement in normal pregnancy as assessed by serum ferritin, serum transferrin saturation and erythrocyte protoporphyrin determinations. Br J Obstet Gynaecol. 1983;90(2):101-7.
15. Chan KK, Chan BC, Lam KF, Tam S, Lao TT. Iron supplement in pregnancy and development of gestational diabetes--a randomised placebo-controlled trial. BJOG. 2009;116(6):789-97.
16. Falahi E, Akbari S, Ebrahimzade F, Gargari BP. Impact of prophylactic iron supplementation in healthy pregnant women on maternal iron status and birth outcome. Food Nutr Bull. 2011;32(3):213-7.
17. Makrides M, Crowther CA, Gibson RA, Gibson RS, Skeaff CM. Efficacy and tolerability oflow-dose iron supplements during pregnancy: a randomized controlled trial. Am J Clin Nutr. 2003;78(1):145-53.
18. Milman N, Agger AO, Nielsen OJ. Iron status markers and serum erythropoietin in 120 mothers and newborn infants. Effect of iron supplementation in normal pregnancy. Acta Obstet Gynecol Scand. 1994;73(3):200-4.
19. Ziaei S, Mehrnia M, Faghihzadeh S. Iron status markers in nonanemic pregnant women with and without iron supplementation. Int J Gynaecol Obstet. 2008;100(2):130-2.
20. Ziaei S, Norrozi M, Faghihzadeh S, Jafarbegloo E. A randomised placebo-controlled trial to determine the effect of iron supplementation on pregnancy outcome in pregnant women with haemoglobin ≥13.2 g/dL. BJOG. 2007;114(6):684-8.
21. Cogswell ME, Parvanta I, Ickes L, Yip R, Brittenham GM. Iron supplementation during pregnancy, anemia and birth weight: a randomized controlled trial. Am J Clin Nutr. 2003;78(4):773-81.
22. Siega-Riz AM, Hartzema AG, Turnbull C, Thorp J, McDonald T, Cogswell ME. The effects of prophylactic iron given in prenatal supplements on iron status and birth outcomes: a randomized controlled trial. Am J Obstet Gynecol. 2006;194(2):512-9.
23. Eskeland B, Malterud K, Ulvik RJ, Hunskaar S. Iron supplementation in pregnancy: is less enough? A randomized, placebo controlled trial of low dose iron supplementation with and without heme iron. Acta Obstet Gynecol Scand. 1997;76(9):822-8.
24. Institute of Medicine. Clinical Preventive Services for Women: Closing the Gaps. Washington, DC: National Academies Press; 2011. Accessed at https://www.iom.edu/Reports/2011/Clinical-Preventive-Services-for-Women-Closing-the-Gaps.aspx on 12 March 2015.
25. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 95: anemia in pregnancy. Obstet Gynecol. 2008;112(1):201-7.
26. American Academy of Family Physicians. Clinical Preventive Service Recommendation: Iron Deficiency Anemia. Leawood, KS: American Academy of Family Physicians; 2015. Accessed at http://www.aafp.org/patient-care/clinical-recommendations/all/iron-deficiency-anemia.html on 12 March 2015.

Current as of: March 2015

Internet Citation: Draft Recommendation Statement: Iron Deficiency Anemia in Pregnant Women: Screening and Supplementation. U.S. Preventive Services Task Force. April 2015.
http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementDraft/iron-deficiency-anemia-in-pregnant-women-screening-and-supplementation

USPSTF Program Office   5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857